Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 28
Filter
3.
Leukemia ; 31(10): 2278, 2017 10.
Article in English | MEDLINE | ID: mdl-28751765

ABSTRACT

This corrects the article DOI: 10.1038/leu.2016.352.

4.
Leukemia ; 31(7): 1611-1621, 2017 07.
Article in English | MEDLINE | ID: mdl-27890931

ABSTRACT

Anti-CD20 monoclonal antibodies (mAb) such as rituximab have been proven to be highly effective at improving outcome in B-cell malignancies. However, many patients ultimately relapse and become refractory to treatment. The glycoengineered anti-CD20 mAb obinutuzumab was developed to induce enhanced antibody-dependent cellular cytotoxicity, antibody-dependent phagocytosis and direct cell death and was shown to lead to improved outcomes in a randomized study in B-CLL. We hypothesized that immune stimulation through Toll-like receptor 7 (TLR7) agonism in combination with obinutuzumab would further enhance lymphoma clearance and the generation of long-term antitumor immune responses. Here we demonstrate, in syngeneic human CD20 (hCD20)-expressing models of lymphoma, that systemic administration of a TLR7 agonist (R848) increases responses when administered in combination with obinutuzumab and protects against disease recurrence. Depletion studies demonstrate that primary antitumor activity is dependent on both NK cells and CD4+ T cells but not on CD8+ T cells. However, both CD4+ and CD8+ T cells appear necessary for the generation of protective immunological memory. Importantly, increased tumor-free survival post obinutuzumab and R848 combination therapy was seen in hCD20 transgenic mice, which express hCD20 on normal B cells. These findings provide a rationale for clinical testing of obinutuzumab in combination with systemically administered TLR7 agonists to further improve outcome.


Subject(s)
Antibodies, Monoclonal, Humanized/pharmacology , Antineoplastic Agents/pharmacology , CD4-Positive T-Lymphocytes/immunology , Imidazoles/pharmacology , Killer Cells, Natural/immunology , Lymphoma/drug therapy , Toll-Like Receptor 7/agonists , Animals , Antibody-Dependent Cell Cytotoxicity/drug effects , Disease Models, Animal , Humans , Lymphocyte Activation/drug effects , Lymphoma/immunology , Mice , Mice, Inbred C57BL , Rituximab/pharmacology
5.
Oncoimmunology ; 4(7): e1016709, 2015 Jul.
Article in English | MEDLINE | ID: mdl-26140246

ABSTRACT

Fractionated radiation therapy (RT) leads to adaptive changes in the tumor microenvironment that may limit the generation of an antitumor immune response. We demonstrated that fractionated RT led to increased tumor cell expression of programmed cell death ligand 1 (PD-L1) in response to CD8+ T cell production of interferon gamma. Our data reveal that the efficacy of fractionated RT can be significantly improved through the generation of durable systemic immune responses when combined with concurrent, but not sequential, blockade of the PD-1/PD-L1 pathway.

6.
Ann Oncol ; 25(9): 1807-1812, 2014 Sep.
Article in English | MEDLINE | ID: mdl-24948692

ABSTRACT

BACKGROUND: Forodesine is a potent inhibitor of purine nucleoside phosphorylase (PNP) that leads to intracellular accumulation of deoxyguanosine triphosphate (dGTP) in T and B cells, resulting in apoptosis. Forodesine has demonstrated impressive antitumor activity in early phase clinical trials in cutaneous T-cell lymphoma (CTCL). PATIENTS AND METHODS: In this phase II study, patients with CTCL who had already failed three or more systemic therapies were recruited. We investigated the response rate, safety and tolerability of oral forodesine treatment in subjects with cutaneous manifestations of CTCL, stages IB, IIA, IIB, III and IVA. The safety population encompassing all stages was used for analysis of accountability, demographics and safety. The efficacy population differed from the safety population by exclusion of stage IB and IIA patients. RESULTS: All 144 patients had performance status 0-2. The median duration of CTCL from diagnosis was 53 months (5-516 months). The median number of pretreatments was 4 (range: 3-15). No complete remissions were observed. In the efficacy group of patients, 11% achieved partial remission and 50% had stable disease. The median time to response was 56 days and the median duration of response was 191 days. A total of 96% of all treated patients reported one or more adverse events (AEs) and 33% reported a serious AE. The majority of AEs were classified as mild or moderate in severity. The most commonly reported AEs (>10%) were peripheral edema, fatigue, insomnia, pruritus, diarrhea, headache and nausea. Overall eight patients died during the study: five due to sepsis and infections, one due to a second malignancy (esophageal cancer), one due to disease progression and one due to liver failure. CONCLUSION: Oral forodesine at a dose of 200 mg daily is feasible and shows partial efficacy in this highly selected CTCL population and some durable responses.


Subject(s)
Antineoplastic Agents/therapeutic use , Mycosis Fungoides/drug therapy , Purine Nucleosides/therapeutic use , Pyrimidinones/therapeutic use , Sezary Syndrome/drug therapy , Skin Neoplasms/drug therapy , Adult , Aged , Aged, 80 and over , Antineoplastic Agents/adverse effects , Apoptosis/drug effects , Female , Humans , Male , Middle Aged , Purine Nucleosides/adverse effects , Purine-Nucleoside Phosphorylase/antagonists & inhibitors , Pyrimidinones/adverse effects , Treatment Failure
7.
Clin Oncol (R Coll Radiol) ; 26(5): 266-76, 2014 May.
Article in English | MEDLINE | ID: mdl-24602563

ABSTRACT

Recent drug discovery developments in the field of small molecule targeted agents have led to much interest in combining these with radiotherapy. There are good preclinical data to suggest this approach worthy of investigation and in this review we discuss how this has translated into recent clinical trials. The outcome of clinical trials investigating radiotherapy/targeted drug combinations published in the last 5 years is discussed, as are trials in progress. The perceived future opportunities and challenges in the development of this exciting area are considered.


Subject(s)
Antineoplastic Agents/therapeutic use , Chemoradiotherapy/methods , Molecular Targeted Therapy/methods , Neoplasms/therapy , Radiation-Sensitizing Agents/therapeutic use , Celecoxib , Clinical Trials as Topic , Cyclooxygenase 2 Inhibitors/pharmacology , ErbB Receptors/drug effects , ErbB Receptors/radiation effects , Humans , Neovascularization, Pathologic/drug therapy , Neovascularization, Pathologic/radiotherapy , Pyrazoles/pharmacology , Sulfonamides/pharmacology , Vascular Endothelial Growth Factor A/drug effects , Vascular Endothelial Growth Factor A/radiation effects
8.
Cell Death Differ ; 20(5): 765-73, 2013 May.
Article in English | MEDLINE | ID: mdl-23412345

ABSTRACT

Effective anticancer treatments often result in the induction of large amounts of tumour cell death. In vivo, such dying tumour cells are a potential source of antigens for T-cell stimulation. Although apoptosis is generally considered nonimmunogenic, recent evidence suggests that some anticancer therapies that induce apoptosis can elicit antitumour immune responses. Here, a doxycycline-inducible, constitutively active caspase-3 ('death switch') was constructed in a murine tumour model to explore the impact of the host immune response to rapid, synchronous and substantial tumour cell apoptosis. In vitro, up to 80% of tumour cells underwent apoptotic cell death within 24 h and death was accompanied by the release of potential 'danger signal' molecules HMGB1 and HSP90. In vivo, death switch induction provoked rapid, pronounced tumour regression in immune-competent and immune-deficient mice, but sustained tumour eradication was observed only in immune-competent mice. Moreover, the majority of mice that were tumour free after death switch induction were protected from further tumour rechallenge. In addition, long-term remission after induction of the death switch was completely abrogated following depletion of CD8 T cells. These data suggest that sustained tumour eradication after substantial tumour apoptosis requires an antitumour host immune response that prevents tumour relapse. In many patients, cancer therapies produce encouraging initial responses that are only short lived. These results provide new insights that may have important implications for further development of strategies that result in long-term tumour clearance after initially effective anticancer treatment.


Subject(s)
Apoptosis/immunology , CD8-Positive T-Lymphocytes/immunology , Caspase 3/metabolism , Melanoma, Experimental/immunology , Animals , Anti-Bacterial Agents/pharmacology , Cell Line, Tumor , Doxycycline/pharmacology , Enzyme Activation , Female , HMGB1 Protein/metabolism , HSP90 Heat-Shock Proteins/metabolism , Mice , Mice, Inbred C57BL , Mice, Inbred NOD , Mice, SCID , Phagocytosis
9.
Br J Radiol ; 85(1018): 1354-62, 2012 Oct.
Article in English | MEDLINE | ID: mdl-22972972

ABSTRACT

In 2011, the Clinical and Translational Radiotherapy Research Working Group (CTRad) of the National Cancer Research Institute brought together UK radiotherapy physics leaders for a think tank meeting. Following a format that CTRad had previously and successfully used with clinical oncologists, 23 departments were asked to complete a pre-meeting evaluation of their radiotherapy physics research infrastructure and the strengths, weaknesses, opportunities and threats within their own centre. These departments were brought together with the CTRad Executive Group and research funders to discuss the current state of radiotherapy physics research, perceived barriers and possible solutions. In this Commentary, we summarise the submitted materials, presentations and discussions from the meeting and propose an action plan. It is clear that there are challenges in both funding and staffing of radiotherapy physics research. Programme and project funding streams sometimes struggle to cater for physics-led work, and increased representation on research funding bodies would be valuable. Career paths for academic radiotherapy physicists need to be examined and an academic training route identified within Modernising Scientific Careers; the introduction of formal job plans may allow greater protection of research time, and should be considered. Improved access to research facilities, including research linear accelerators, would enhance research activity and pass on developments to patients more quickly; research infrastructure could be benchmarked against centres in the UK and abroad. UK National Health Service departments wishing to undertake radiotherapy research, with its attendant added value for patients, need to develop a strategy with their partner higher education institution, and collaboration between departments may provide enhanced opportunities for funded research.


Subject(s)
Biomedical Research/organization & administration , Radiation Oncology/organization & administration , Radiotherapy/methods , Biomedical Research/economics , Career Mobility , Clinical Trials as Topic , Health Physics/economics , Health Physics/organization & administration , Physics/economics , Physics/organization & administration , Radiation Oncology/economics , Radiation Oncology/instrumentation , Radiotherapy/economics , Radiotherapy/instrumentation , Research Support as Topic , Technology, Radiologic , United Kingdom
11.
Br J Cancer ; 104(4): 719-25, 2011 Feb 15.
Article in English | MEDLINE | ID: mdl-21245866

ABSTRACT

PURPOSE: Treatment efficacy and toxicity are difficult to predict in lymphoma patients. In this study, the utility of circulating biomarkers in predicting and/or monitoring treatment efficacy/toxicity were investigated. PATIENTS AND METHODS: Circulating biomarkers of cell death (nucleosomal DNA (nDNA) and cytokeratin 18 (CK18)), and circulating FLT3 ligand, a potential biomarker of myelosuppression, were assessed before and serially after standard chemotherapy in 49 patients with Hodgkin and non-Hodgkin lymphoma. Cytokeratin 18 is not expressed in lymphoma cells so is a potential biomarker of epithelial toxicity in this setting. Tumour response was assessed before and after completion of chemotherapy by 2D and 3D computed tomography radiological response. RESULTS: Baseline nDNA level was significantly higher in all lymphoma subtypes compared with 61 healthy controls and was prognostic for progression-free survival in diffuse large B-cell lymphoma (DLBCL). Decreases in nDNA levels were observed in the first week after chemotherapy; in FL, early falls in nDNA predicted for long remission following therapy. In DLBCL, elevations in nDNA occurred in cases with progressive disease. Circulating CK18 increased within 48 h of chemotherapy and was significantly higher in patients experiencing epithelial toxicity graded >3 by Common Terminology for Classification of Adverse Events criteria. FLT3 ligand was elevated within 3-8 days of chemotherapy initiation and predicted those patients who subsequently developed neutropenic sepsis. CONCLUSION: These data suggest circulating biomarkers contribute useful information regarding tumour response and toxicity in patients receiving standard chemotherapy and have potential utility in the development of individualised treatment approaches in lymphoma. These biomarkers are now being tested within multicentre phase III trials to progress their qualification.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/pharmacokinetics , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Biomarkers, Tumor/blood , Lymphoma/diagnosis , Lymphoma/drug therapy , Adolescent , Adult , Aged , Aged, 80 and over , Antibodies, Monoclonal, Murine-Derived/administration & dosage , Antibodies, Monoclonal, Murine-Derived/adverse effects , Antibodies, Monoclonal, Murine-Derived/pharmacokinetics , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Biomarkers, Pharmacological/analysis , Biomarkers, Pharmacological/blood , Biomarkers, Tumor/analysis , Bleomycin/adverse effects , Bleomycin/pharmacokinetics , Bleomycin/therapeutic use , Cyclophosphamide/adverse effects , Cyclophosphamide/pharmacokinetics , Cyclophosphamide/therapeutic use , DNA/analysis , DNA/blood , Dacarbazine/adverse effects , Dacarbazine/pharmacokinetics , Dacarbazine/therapeutic use , Doxorubicin/adverse effects , Doxorubicin/pharmacokinetics , Doxorubicin/therapeutic use , Female , Humans , Keratin-18/analysis , Keratin-18/blood , Lymphoma/blood , Lymphoma/metabolism , Male , Middle Aged , Nucleosomes/genetics , Predictive Value of Tests , Prednisone/adverse effects , Prednisone/pharmacokinetics , Prednisone/therapeutic use , Prognosis , Rituximab , Vinblastine/adverse effects , Vinblastine/pharmacokinetics , Vinblastine/therapeutic use , Vincristine/adverse effects , Vincristine/pharmacokinetics , Vincristine/therapeutic use , Young Adult , fms-Like Tyrosine Kinase 3/analysis , fms-Like Tyrosine Kinase 3/blood
12.
J Immunol Methods ; 360(1-2): 30-8, 2010 Aug 31.
Article in English | MEDLINE | ID: mdl-20547164

ABSTRACT

Rituximab is a chimeric anti-CD20 monoclonal antibody that has revolutionised the treatment of many B-cell malignancies, and is now increasingly being used in non-malignant conditions such as auto-immune disorders. Serum rituximab levels are highly variable in patients receiving similar 'standard' approved doses. Little is known regarding the factors that affect serum rituximab concentration and that in turn may influence clinical outcome. In order to provide a tool that may ultimately enable patient specific dosing of rituximab therapy, we have validated a reliable, robust ELISA for the quantitation of serum rituximab levels to provide accurate pharmacokinetic (PK) data that will guide the optimisation of rituximab dosing regimes. Extensive validation of the assay was performed in order to utilise the assay for clinical applications. The within and between day plate coating reproducibility was tested and proved a robust starting platform for the assay. The within day precision for the assay was determined using spiked serum samples and was shown to have a coefficient of variation (CV) of <10% with an accuracy between 91 and 125%. The between day precision (CV) was <25% with an accuracy between 95 and 109%. Dilution linearity and parallelism were demonstrated. Spike recovery for all concentrations and donors was shown to be within +/-15% on average, with a CV below 10%. This assay is highly accurate and reproducible in determining the levels of rituximab in spiked serum samples. It meets stringent acceptance criteria, is fit for purpose, and is currently being applied to several clinical trials incorporating rituximab in the treatment of lymphoma. This assay represents a useful tool for clinical application of this widely used therapeutic.


Subject(s)
Antibodies, Monoclonal/blood , Enzyme-Linked Immunosorbent Assay/methods , Lymphoma, B-Cell/blood , Antibodies, Monoclonal/therapeutic use , Antibodies, Monoclonal, Murine-Derived , Antigens, CD20/genetics , Antigens, CD20/immunology , Drug Dosage Calculations , Humans , K562 Cells , Lymphoma, B-Cell/drug therapy , Lymphoma, B-Cell/immunology , Reference Standards , Reference Values , Reproducibility of Results , Rituximab , Sensitivity and Specificity , Validation Studies as Topic
14.
Cell Biol Int ; 29(12): 1005-11, 2005 Dec.
Article in English | MEDLINE | ID: mdl-16314119

ABSTRACT

Following irradiation p53-function-deficient tumour cells undergo mitotic catastrophe and form endopolyploid cells. A small proportion of these segregates nuclei, and give rise to viable descendants. Here we studied this process in five tumour cell lines. After mitotic failure, tumour cells enter the endocycle and form mono-nucleated or multi-nucleated giant cells (MOGC and MNGC). MNGC arise from arrested anaphases, MOGC, from arrested metaphases. In both cases the individual genomes establish a radial pattern by links to a single microtubule organizing centre. Segregation of genomes is also ordered. MNGC present features of mitosis being resumed from late anaphase. In MOGC the sub-nuclei retain arrangement of stacked metaphase plates and are separated by folds of the nuclear envelope. Mitosis then resumes in sub-nuclei directly from metaphase. The data presented indicate that endopolyploid tumour cells preserve the integrity of individual genomes and can potentially re-initiate mitosis from the point at which it was interrupted.


Subject(s)
Chromosome Segregation , Mitosis , Polyploidy , Cell Line, Tumor , HeLa Cells , Humans , Jurkat Cells , Metaphase , Tumor Suppressor Protein p53/genetics , Tumor Suppressor Protein p53/physiology
15.
Clin Oncol (R Coll Radiol) ; 17(3): 174-84, 2005 May.
Article in English | MEDLINE | ID: mdl-15901002

ABSTRACT

The aetiology and clinical management of primary cutaneous T-cell lymphoma (CTCL) and specifically of mycosis fungoides and Sezary syndrome are poorly defined. Interesting new insights into CTCL disease biology as well as a number of emerging of novel therapeutic interventions make this an increasingly interesting area for dermatologists and oncologists involved in the treatment of CTCL. This review article covers much of this new information including new drugs, such as denileukin diftitox (Ontak) a targeted cytotoxic biological agent, Bexarotene an RXR selective retinoid, anti-CD4 monoclonal antibodies (mAb), new cytotoxics agents and vaccines.


Subject(s)
Lymphoma, T-Cell, Cutaneous/diagnosis , Lymphoma, T-Cell, Cutaneous/therapy , Humans , Mycosis Fungoides/diagnosis , Mycosis Fungoides/therapy , Prognosis
16.
Clin Oncol (R Coll Radiol) ; 14(6): 468-71, 2002 Dec.
Article in English | MEDLINE | ID: mdl-12512969

ABSTRACT

The majority of newly diagnosed patients with Hodgkin's lymphoma are expected to survive because of effective therapies established during the last 40 years. Long-term observations from large populations of treated patients have disclosed a variety of late effects of the disease and its therapy that have contributed morbidity and excess mortality to Hodgkin's lymphoma survivors. As such complications have been recognized treatment approaches have been modified. Here we report a case of cervical neuropathy secondary to mantle radiotherapy, a complication not previously reported in the literature.


Subject(s)
Hodgkin Disease/radiotherapy , Peripheral Nervous System Diseases/etiology , Radiation Injuries/pathology , Adult , Female , Humans , Morbidity , Neck/innervation , Radiotherapy/adverse effects
17.
Clin Oncol (R Coll Radiol) ; 13(5): 372-7, 2001.
Article in English | MEDLINE | ID: mdl-11716233

ABSTRACT

Hypercalcaemia is the most common serious metabolic complication of malignancy. Recent advances have significantly increased our understanding of the pathophysiology of hypercalcaemia of malignancy and revealed the importance of parathyroid hormone-related protein (PTHrP) in a wide range of physiological and pathological processes. This review examines the pathophysiology of hypercalcaemia of malignancy, focusing on the role of PTHrP before discussing further pathological and physiological processes in which PTHrP may be implicated, and the impact of this knowledge on the management of malignant disease.


Subject(s)
Hypercalcemia/physiopathology , Neoplasms/physiopathology , Bone Neoplasms/metabolism , Bone Neoplasms/secondary , Cachexia/complications , Cachexia/metabolism , Diagnosis, Differential , Hypercalcemia/etiology , Hypercalcemia/metabolism , Neoplasm Proteins/analysis , Neoplasms/complications , Parathyroid Hormone-Related Protein , Proteins/analysis
18.
Expert Opin Pharmacother ; 2(6): 953-61, 2001 Jun.
Article in English | MEDLINE | ID: mdl-11585011

ABSTRACT

The availability of rituximab and the possible imminent availability of two new radiolabelled monoclonal anti-CD20 antibodies (Yttrium-90 (90Y)-ibritumomab and Iodine-131(131I)-tositumomab) have captured much attention in the treatment of lymphoma. The chimeric monoclonal anti-CD20 antibody, rituximab has truly heralded a new era for the treatment of lymphoma and human malignancies. The full potential of antibody-based therapy to improve the outcome in patients with B-cell non-Hodgkin's lymphoma has yet to be defined, but recent data suggests that the combination of chemotherapy plus rituximab may significantly improve outcome for patients with aggressive lymphoma over chemotherapy alone. Highly promising data are also emerging for the use of rituximab in combination with chemotherapy in other types of lymphoma. New advances in antibody therapy, driven by new technologies and defining novel antigen targets, offer the promise of more effective tumour specific therapies. Combinations of antibodies, either conjugated with radioisotopes or unlabelled, used with chemotherapy are likely to provide definitive advances in the treatment of lymphoma in the immediate future.


Subject(s)
Antibodies, Monoclonal/therapeutic use , Antineoplastic Agents/therapeutic use , Lymphoma/therapy , Alemtuzumab , Antibodies, Monoclonal/immunology , Antibodies, Monoclonal, Humanized , Antibodies, Monoclonal, Murine-Derived , Antibodies, Neoplasm/therapeutic use , Antigens, CD20/immunology , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Clinical Trials as Topic , Combined Modality Therapy , Guidelines as Topic , Humans , Immunoconjugates/therapeutic use , Iodine Radioisotopes/therapeutic use , Lymphoma/drug therapy , Lymphoma/radiotherapy , Radioimmunotherapy , Rituximab
19.
Cell Biol Int ; 24(9): 621-33, 2000.
Article in English | MEDLINE | ID: mdl-10964452

ABSTRACT

The relationships between delayed apoptosis, polyploid 'giant' cells and reproductive survivors were studied in p53-mutated lymphoma cells after DNA damage. Following severe genotoxic insult with irradiation or chemotherapy, cells arrest at the G(2)-M cell cycle check-point for up to 5 days before undergoing a few rounds of aberrant mitoses. The cells then enter endoreduplication cycles resulting in the formation of polyploid giant cells. Subsequently the majority of the giant cells die, providing the main source of delayed apoptosis; however, a small proportion survives. Kinetic analyses show a reciprocal relationship between the polyploid cells and the diploid stem line, with the stem line suppressed during polyploid cell formation and restituted after giant cell disintegration. The restituted cell-line behaves with identical kinetics to the parent line, once re-irradiated. When giant cells are isolated and followed in labelling experiments, the clonogenic survivors appear to arise from these cells. These findings imply that an exchange exists between the endocyclic (polyploid) and mitotic (diploid or tetraploid) populations during the restitution period and that giant cells are not always reproductively dead as previously supposed. We propose that the formation of giant cells and their subsequent complex breakdown and subnuclear reorganization may represent an important response of p53-mutated tumours to DNA damaging agents and provide tumours with a mechanism of repair and resistance to such treatments.


Subject(s)
DNA Damage/radiation effects , Giant Cells/radiation effects , Polyploidy , Tumor Suppressor Protein p53/physiology , Apoptosis/radiation effects , Cell Separation , Cell Survival , Giant Cells/cytology , Humans , Mitosis/radiation effects , Tumor Cells, Cultured , Tumor Suppressor Protein p53/genetics
20.
Cell Biol Int ; 24(9): 635-48, 2000.
Article in English | MEDLINE | ID: mdl-10964453

ABSTRACT

Polyploid giant cells are produced as part of the response of p53 mutant Burkitt's lymphoma cell lines to high doses of irradiation. Polyploid giant cells arise by endo-reduplication in the first week after a single 10 Gray dose of irradiation. Within the giant cells a sub-nuclear structure is apparent and within this, sub-nuclear autonomy is evident, as displayed by independent nuclear structure and DNA replication in different parts of the nucleus. The majority of these cells soon die as apoptotic polykaryons. However, approximately 10-20% of giant cells remain viable into the second week after irradiation and begin vigorous extrusion of large degraded chromatin masses. During the second week, the giant cells begin to reconstruct their nuclei into polyploid 'bouquets', where chromosome double-loops are formed. Subsequently, the bouquets return to an interphase state and separate into several secondary nuclei. The individual sub-nuclei then resume DNA synthesis with mitotic divisions and sequester cytoplasmic territories around themselves, giving rise to the secondary cells, which continue mitotic propagation. This process of giant cell formation, reorganization and breakdown appears to provide an additional mechanism for repairing double-strand DNA breaks within tumour cells.


Subject(s)
Giant Cells/radiation effects , Mitosis/radiation effects , Apoptosis/radiation effects , Cell Nucleus/radiation effects , Chromatin/radiation effects , Giant Cells/physiology , Humans , Mitosis/physiology , Time Factors , Tumor Cells, Cultured
SELECTION OF CITATIONS
SEARCH DETAIL
...